Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Companyโs proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Companyโs segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
์ข
๋ชฉ ์ฝ๋ PGEN
ํ์ฌ ์ด๋ฆPrecigen Inc
์์ฅ์ผAug 08, 2013
CEOSabzevari (Helen)
์ง์ ์143
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃAug 08
์ฃผ์20374 Seneca Meadows Parkway
๋์GERMANTOWN
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ20876
์ ํ13015569900
์น์ฌ์ดํธhttps://precigen.com/
์ข
๋ชฉ ์ฝ๋ PGEN
์์ฅ์ผAug 08, 2013
CEOSabzevari (Helen)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์